Index RUT
P/E -
EPS (ttm) -5.45
Insider Own 3.48%
Shs Outstand 101.64M
Perf Week -3.27%
Market Cap 6.83B
Forward P/E -
EPS next Y -3.19
Insider Trans -6.40%
Shs Float 100.94M
Perf Month -8.50%
Income -526.24M
PEG -
EPS next Q -1.14
Inst Own 108.35%
Short Float 13.91%
Perf Quarter -21.03%
Sales 7.53M
P/S 907.47
EPS this Y 18.27%
Inst Trans -1.40%
Short Ratio 6.89
Perf Half Y 100.49%
Book/sh -3.80
P/B -
EPS next Y 28.40%
ROA -57.23%
Short Interest 14.04M
Perf Year 75.93%
Cash/sh 5.88
P/C 11.11
EPS next 5Y 15.00%
ROE -
52W Range 25.98 - 110.25
Perf YTD -21.74%
Dividend Est. -
P/FCF -
EPS past 5Y -22.79%
ROI -154.11%
52W High -40.73%
Beta 0.71
Dividend TTM -
Quick Ratio 6.12
Sales past 5Y 12.30%
Gross Margin -82.78%
52W Low 151.50%
ATR (14) 2.91
Dividend Ex-Date -
Current Ratio 6.12
EPS Y/Y TTM -28.21%
Oper. Margin -6589.71%
RSI (14) 40.32
Volatility 3.19% 3.95%
Employees 423
Debt/Eq -
Sales Y/Y TTM -92.04%
Profit Margin -6988.63%
Recom 1.44
Target Price 96.06
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 4.77%
Payout -
Rel Volume 0.31
Prev Close 64.80
Sales Surprise -78.05%
EPS Surprise -43.97%
Sales Q/Q -14.56%
Earnings May 08 AMC
Avg Volume 2.04M
Price 65.34
SMA20 -6.54%
SMA50 -7.06%
SMA200 27.87%
Trades
Volume 641,688
Change 0.83%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-24-24 Downgrade
UBS
Buy → Neutral
$61 → $92
Jan-05-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$60 → $90
Nov-09-23 Initiated
Goldman
Buy
$50
Nov-07-23 Initiated
B. Riley Securities
Buy
$66
Aug-15-23 Initiated
SVB Securities
Outperform
$58
Feb-17-23 Initiated
BofA Securities
Neutral
$49
Dec-23-22 Reiterated
Needham
Buy
$60 → $58
Dec-20-22 Initiated
Truist
Buy
$60
Oct-11-22 Initiated
UBS
Buy
$80
Jan-28-22 Initiated
Goldman
Buy
$74
Dec-22-21 Initiated
Oppenheimer
Outperform
$55
Dec-10-21 Initiated
JP Morgan
Overweight
$58
Oct-07-21 Initiated
Jefferies
Buy
$75
Mar-12-21 Initiated
Wolfe Research
Outperform
$50
Feb-18-21 Initiated
Barclays
Overweight
$28
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$22 → $41
Oct-29-20 Initiated
Goldman
Neutral
$16
Jul-10-20 Initiated
Raymond James
Strong Buy
$39
May-05-20 Initiated
Mizuho
Buy
$31
Apr-09-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$25
Show Previous Ratings
Today 04:44PM
06:00AM
Apr-24-24 04:00PM
Apr-10-24 09:27AM
07:30AM
07:00PM
Loading…
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-13-24 02:25PM
Mar-12-24 06:46AM
(Thomson Reuters StreetEvents)
04:00PM
Loading…
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
(FierceBiotech.com) -9.75%
10:22AM
07:30AM
Feb-27-24 05:10PM
04:42PM
04:17PM
(Associated Press Finance)
04:00PM
Feb-13-24 04:00PM
Feb-12-24 12:38AM
Feb-09-24 10:01AM
(Investor's Business Daily)
Feb-08-24 09:10AM
04:00PM
Loading…
Feb-06-24 04:00PM
Feb-05-24 05:30PM
(The Wall Street Journal)
Jan-29-24 07:30AM
Jan-25-24 07:30AM
Jan-18-24 01:00PM
Jan-12-24 04:40PM
02:47PM
01:07PM
05:27AM
Jan-11-24 04:22PM
04:05PM
12:58PM
(The Wall Street Journal)
12:54PM
12:47PM
(The Wall Street Journal)
12:30PM
Jan-10-24 01:04PM
Jan-09-24 01:17PM
Jan-08-24 05:14PM
(The Wall Street Journal) +15.29%
04:42PM
(Investor's Business Daily)
02:12PM
(Investor's Business Daily)
01:11PM
(The Wall Street Journal)
01:05PM
Jan-03-24 04:00PM
06:45AM
Jan-02-24 04:00PM
Dec-29-23 01:01PM
Dec-28-23 03:09PM
(Investor's Business Daily)
02:43PM
09:44AM
Dec-27-23 05:26PM
(Yahoo Finance Video) +82.54%
03:52PM
01:59PM
01:00PM
12:21PM
(Associated Press Finance)
09:41AM
08:34AM
07:39AM
07:32AM
07:30AM
Dec-26-23 04:00PM
Dec-15-23 10:22AM
Dec-07-23 07:30AM
Dec-01-23 04:00PM
Nov-29-23 04:00PM
Nov-10-23 03:04PM
Nov-04-23 12:16PM
Nov-03-23 04:00PM
11:43AM
(Thomson Reuters StreetEvents)
11:20AM
Nov-02-23 06:59PM
05:25PM
04:24PM
(Associated Press Finance)
04:00PM
09:55AM
Nov-01-23 04:00PM
Oct-31-23 02:24PM
12:43PM
Oct-26-23 09:08PM
Oct-23-23 04:00PM
Oct-19-23 07:30AM
Oct-09-23 07:53AM
Oct-06-23 12:45PM
Oct-05-23 04:00PM
Oct-03-23 04:00PM
Oct-02-23 04:00PM
Sep-28-23 07:30AM
Sep-15-23 01:05AM
Sep-14-23 01:02AM
Sep-09-23 03:59PM
Sep-07-23 04:29PM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HENDERSON JOHN T Director Apr 25 '24 Sale 64.54 10,562 681,671 32,070 Apr 25 06:54 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Option Exercise 6.67 28,605 190,795 171,172 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Sale 74.31 32,605 2,422,918 138,567 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Option Exercise 6.67 28,604 190,789 167,577 Mar 05 04:05 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Sale 67.56 32,604 2,202,606 138,973 Mar 05 04:05 PM HENDERSON JOHN T Director Feb 14 '24 Option Exercise 4.44 5,000 22,200 47,632 Feb 14 04:04 PM HENDERSON JOHN T Director Feb 14 '24 Sale 76.48 5,000 382,400 42,632 Feb 14 04:04 PM Blum Robert I President & CEO Feb 13 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 13 04:01 PM Blum Robert I President & CEO Feb 13 '24 Sale 76.85 12,500 960,625 441,797 Feb 13 04:01 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Option Exercise 6.67 28,605 190,795 175,578 Feb 06 04:43 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Sale 79.30 32,605 2,585,496 142,973 Feb 06 04:43 PM Blum Robert I President & CEO Jan 31 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 02 04:41 PM Blum Robert I President & CEO Jan 31 '24 Sale 79.57 12,500 994,625 441,797 Feb 02 04:41 PM Blum Robert I President & CEO Jan 19 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 22 05:19 PM Blum Robert I President & CEO Jan 19 '24 Sale 81.42 12,500 1,017,750 441,797 Jan 22 05:19 PM HENDERSON JOHN T Director Jan 12 '24 Option Exercise 4.44 5,000 22,200 47,632 Jan 12 05:20 PM HENDERSON JOHN T Director Jan 12 '24 Sale 85.14 5,000 425,700 42,632 Jan 12 05:20 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Option Exercise 7.96 11,678 92,957 162,651 Jan 04 04:36 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Sale 86.98 15,678 1,363,712 146,973 Jan 04 04:36 PM Blum Robert I President & CEO Jan 02 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 02 05:55 PM Blum Robert I President & CEO Jan 02 '24 Sale 85.08 12,500 1,063,500 441,797 Jan 02 05:55 PM WIERENGA WENDALL Director Dec 27 '23 Option Exercise 4.44 10,000 44,400 23,653 Dec 27 04:11 PM WIERENGA WENDALL Director Dec 27 '23 Sale 73.60 10,000 736,000 18,653 Dec 27 04:11 PM HENDERSON JOHN T Director Dec 18 '23 Option Exercise 6.72 13,020 87,494 44,838 Dec 19 04:12 PM Blum Robert I President & CEO Dec 18 '23 Option Exercise 6.67 12,500 83,375 454,297 Dec 19 04:13 PM Blum Robert I President & CEO Dec 18 '23 Sale 36.95 12,500 461,875 441,797 Dec 19 04:13 PM HENDERSON JOHN T Director Dec 18 '23 Sale 36.34 2,458 89,324 42,380 Dec 19 04:12 PM Blum Robert I President & CEO Nov 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Dec 01 04:15 PM Blum Robert I President & CEO Nov 30 '23 Sale 32.99 12,500 412,375 441,417 Dec 01 04:15 PM Blum Robert I President & CEO Nov 15 '23 Option Exercise 6.67 12,500 83,375 453,917 Nov 15 05:22 PM Blum Robert I President & CEO Nov 15 '23 Sale 34.57 12,500 432,125 441,417 Nov 15 05:22 PM Malik Fady Ibraham EVP Research & Development Nov 09 '23 Sale 35.40 2,500 88,500 150,664 Nov 09 04:35 PM Blum Robert I President & CEO Oct 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 30 04:02 PM Blum Robert I President & CEO Oct 30 '23 Sale 32.17 12,500 402,125 441,417 Oct 30 04:02 PM Blum Robert I President & CEO Oct 16 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 16 05:57 PM Blum Robert I President & CEO Oct 16 '23 Sale 33.70 12,500 421,250 441,417 Oct 16 05:57 PM Malik Fady Ibraham EVP Research & Development Oct 12 '23 Sale 35.89 2,500 89,725 153,164 Oct 12 06:39 PM Blum Robert I President & CEO Oct 06 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 06 04:52 PM Blum Robert I President & CEO Oct 06 '23 Sale 30.00 12,500 375,000 441,417 Oct 06 04:52 PM Malik Fady Ibraham EVP Research & Development Sep 14 '23 Sale 34.86 2,500 87,150 155,664 Sep 14 04:09 PM Blum Robert I President & CEO Sep 13 '23 Option Exercise 6.67 12,500 83,375 453,917 Sep 13 04:09 PM Blum Robert I President & CEO Sep 13 '23 Sale 34.90 12,500 436,206 441,417 Sep 13 04:09 PM Blum Robert I President & CEO Aug 25 '23 Option Exercise 7.70 12,500 96,275 453,917 Aug 28 06:45 PM Blum Robert I President & CEO Aug 25 '23 Sale 33.99 12,500 424,875 441,417 Aug 28 06:45 PM WIERENGA WENDALL Director Aug 21 '23 Option Exercise 6.72 6,020 40,454 24,225 Aug 21 04:01 PM WIERENGA WENDALL Director Aug 21 '23 Sale 32.02 6,020 192,760 18,205 Aug 21 04:01 PM Blum Robert I President & CEO Aug 11 '23 Option Exercise 9.54 12,500 119,287 453,125 Aug 11 04:18 PM Blum Robert I President & CEO Aug 11 '23 Sale 32.37 12,500 404,589 441,417 Aug 11 04:18 PM Malik Fady Ibraham EVP Research & Development Aug 10 '23 Sale 31.70 2,500 79,250 158,164 Aug 10 04:14 PM Blum Robert I President & CEO Aug 01 '23 Option Exercise 9.65 12,500 120,625 452,108 Aug 01 04:57 PM Blum Robert I President & CEO Aug 01 '23 Sale 32.63 12,500 407,856 441,417 Aug 01 04:57 PM Blum Robert I President & CEO Jul 13 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 13 04:10 PM Blum Robert I President & CEO Jul 13 '23 Sale 35.28 12,500 440,940 441,417 Jul 13 04:10 PM Malik Fady Ibraham EVP Research & Development Jul 13 '23 Sale 35.37 2,500 88,425 160,664 Jul 13 04:09 PM Bhanji Muna Director Jul 07 '23 Sale 34.12 2,000 68,235 14,031 Jul 07 04:17 PM Blum Robert I President & CEO Jul 03 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 05 04:18 PM Blum Robert I President & CEO Jul 03 '23 Sale 32.60 12,500 407,500 441,417 Jul 05 04:18 PM Blum Robert I President & CEO Jun 12 '23 Option Exercise 9.65 12,500 120,625 453,917 Jun 12 05:49 PM Blum Robert I President & CEO Jun 12 '23 Sale 37.06 12,500 463,250 441,417 Jun 12 05:49 PM Malik Fady Ibraham EVP Research & Development Jun 08 '23 Sale 38.07 2,500 95,175 163,164 Jun 08 04:31 PM Blum Robert I President & CEO May 31 '23 Option Exercise 9.65 12,500 120,625 453,558 Jun 01 05:06 PM Blum Robert I President & CEO May 31 '23 Sale 37.67 12,500 470,875 441,058 Jun 01 05:06 PM Blum Robert I President & CEO May 16 '23 Option Exercise 9.65 12,500 120,625 453,558 May 16 04:33 PM Blum Robert I President & CEO May 16 '23 Sale 37.41 12,500 467,625 441,058 May 16 04:33 PM HENDERSON JOHN T Director May 15 '23 Option Exercise 6.78 4,166 28,245 29,586 May 15 04:07 PM HENDERSON JOHN T Director May 15 '23 Sale 37.77 4,166 157,350 25,420 May 15 04:07 PM Malik Fady Ibraham EVP Research & Development May 11 '23 Sale 39.50 1,787 70,586 165,396 May 11 05:26 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Option Exercise 7.96 7,000 55,720 174,183 May 03 04:46 PM Malik Fady Ibraham EVP Research & Development May 03 '23 Sale 40.00 7,000 280,000 167,183 May 03 04:46 PM Blum Robert I President & CEO Apr 28 '23 Option Exercise 9.65 12,500 120,625 453,558 Apr 28 04:01 PM Blum Robert I President & CEO Apr 28 '23 Sale 37.68 12,500 471,000 441,058 Apr 28 04:01 PM
Index -
P/E -
EPS (ttm) -2.56
Insider Own 8.11%
Shs Outstand 144.34M
Perf Week 2.24%
Market Cap 6.06B
Forward P/E -
EPS next Y -3.24
Insider Trans -3.78%
Shs Float 133.94M
Perf Month -6.87%
Income -366.02M
PEG -
EPS next Q -1.01
Inst Own 97.21%
Short Float 7.12%
Perf Quarter -19.23%
Sales 788.14M
P/S 7.69
EPS this Y -53.13%
Inst Trans -4.53%
Short Ratio 8.86
Perf Half Y -6.27%
Book/sh 2.68
P/B 15.52
EPS next Y 17.32%
ROA -13.25%
Short Interest 9.53M
Perf Year 16.34%
Cash/sh 16.04
P/C 2.59
EPS next 5Y -
ROE -76.29%
52W Range 34.32 - 54.44
Perf YTD -17.79%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -15.91%
52W High -23.61%
Beta 0.40
Dividend TTM -
Quick Ratio 5.83
Sales past 5Y 13.97%
Gross Margin 95.99%
52W Low 21.18%
ATR (14) 1.08
Dividend Ex-Date -
Current Ratio 5.90
EPS Y/Y TTM -34.71%
Oper. Margin -44.87%
RSI (14) 43.24
Volatility 2.82% 2.52%
Employees 927
Debt/Eq 5.09
Sales Y/Y TTM 34.16%
Profit Margin -46.44%
Recom 1.84
Target Price 57.61
Option/Short Yes / Yes
LT Debt/Eq 4.95
EPS Q/Q 82.93%
Payout -
Rel Volume 0.51
Prev Close 41.84
Sales Surprise 86.65%
EPS Surprise 92.53%
Sales Q/Q 113.82%
Earnings May 07 BMO
Avg Volume 1.08M
Price 41.59
SMA20 -1.57%
SMA50 -4.31%
SMA200 -8.35%
Trades
Volume 550,663
Change -0.60%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-10-24 Upgrade
Wolfe Research
Peer Perform → Outperform
$58
Jan-02-24 Upgrade
BofA Securities
Neutral → Buy
$52 → $62
Oct-23-23 Upgrade
BofA Securities
Underperform → Neutral
$33 → $52
Sep-29-23 Initiated
Raymond James
Strong Buy
$63
Jul-31-23 Upgrade
Citigroup
Neutral → Buy
$36 → $60
Jun-07-23 Resumed
Piper Sandler
Overweight
$58
May-04-23 Upgrade
Citigroup
Sell → Neutral
$30 → $36
Mar-21-23 Initiated
Bernstein
Underperform
$31
Dec-21-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$56 → $40
Sep-09-22 Resumed
Morgan Stanley
Overweight
$57
Jul-18-22 Resumed
Oppenheimer
Outperform
$59
Mar-31-22 Resumed
Piper Sandler
Overweight
$54
Mar-01-22 Initiated
Guggenheim
Buy
$64
Mar-01-22 Initiated
Citigroup
Sell
$26
Feb-01-22 Downgrade
BofA Securities
Buy → Underperform
$40 → $30
Dec-14-21 Upgrade
William Blair
Mkt Perform → Outperform
May-07-21 Upgrade
UBS
Sell → Neutral
$33 → $37.50
Mar-01-21 Upgrade
Barclays
Underweight → Equal Weight
$50 → $52
Dec-16-20 Initiated
UBS
Sell
$34
Dec-15-20 Upgrade
Cowen
Market Perform → Outperform
Show Previous Ratings
Apr-25-24 07:00AM
Apr-23-24 07:05AM
Apr-07-24 09:48AM
Apr-01-24 07:05AM
Mar-28-24 07:05AM
09:09AM
Loading…
Mar-25-24 09:09AM
08:18AM
Mar-22-24 11:30AM
Mar-21-24 03:00PM
(The Wall Street Journal)
Mar-17-24 08:50AM
Mar-14-24 10:40AM
Mar-13-24 07:17AM
07:07AM
07:00AM
Mar-06-24 07:30AM
09:05AM
Loading…
Feb-29-24 09:05AM
Feb-28-24 07:05AM
Feb-22-24 12:12PM
10:59AM
10:29AM
02:20AM
(Thomson Reuters StreetEvents)
Feb-21-24 11:31AM
09:30AM
08:05AM
07:06AM
(Associated Press Finance)
07:00AM
Feb-15-24 09:15AM
07:00AM
Feb-14-24 10:00AM
Feb-09-24 10:44AM
07:00AM
Loading…
Feb-08-24 07:00AM
Feb-07-24 07:05AM
Jan-23-24 01:23PM
Jan-22-24 07:26AM
07:09AM
07:00AM
04:47AM
Jan-18-24 07:58PM
Jan-08-24 08:00AM
07:03AM
Jan-03-24 08:00AM
Dec-30-23 07:01AM
Dec-27-23 10:34PM
Dec-24-23 11:01AM
Dec-21-23 06:55PM
05:45PM
05:35PM
Dec-20-23 01:50PM
07:05AM
Dec-19-23 10:45AM
Dec-18-23 04:01PM
Dec-14-23 04:05PM
Dec-07-23 08:47PM
Nov-16-23 08:00AM
Nov-13-23 09:46AM
Nov-11-23 11:30AM
Nov-09-23 12:42PM
Nov-04-23 01:01PM
Nov-03-23 06:36PM
(Morningstar Research) +7.91%
09:44AM
07:05AM
05:09AM
(Thomson Reuters StreetEvents)
Nov-02-23 12:36PM
09:30AM
07:19AM
(Associated Press Finance)
07:00AM
Oct-31-23 10:01AM
Oct-30-23 03:46PM
Oct-26-23 10:02AM
Oct-19-23 07:05AM
Oct-16-23 10:43AM
Oct-05-23 10:26AM
Oct-04-23 07:00AM
Oct-02-23 01:17PM
Sep-30-23 05:10AM
Sep-29-23 05:01AM
Sep-28-23 12:02PM
10:06AM
Sep-27-23 09:58AM
08:00AM
07:00AM
Sep-26-23 04:19PM
(Investor's Business Daily) +8.49%
07:28AM
07:10AM
07:00AM
Sep-20-23 01:03PM
Sep-12-23 07:05AM
Sep-08-23 11:30AM
Aug-30-23 07:05AM
Aug-11-23 12:37PM
Aug-10-23 11:31AM
10:04AM
09:55AM
04:56AM
(Thomson Reuters StreetEvents)
01:01AM
Aug-09-23 09:30AM
08:15AM
07:09AM
07:00AM
Aug-03-23 07:05AM
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Baroldi Joseph EVP, Chief Business Officer Apr 16 '24 Sale 41.60 4,006 166,641 19,631 Apr 17 05:19 PM Birchler Brian EVP, Corp and Development Ops Apr 16 '24 Sale 41.66 905 37,698 46,156 Apr 17 05:16 PM Baroldi Joseph EVP, Chief Business Officer Apr 15 '24 Option Exercise 0.00 10,838 0 23,637 Apr 17 05:19 PM Birchler Brian EVP, Corp and Development Ops Apr 15 '24 Option Exercise 0.00 1,875 0 47,061 Apr 17 05:16 PM Monia Brett P Chief Executive Officer Feb 16 '24 Sale 44.49 387 17,219 173,751 Feb 16 07:47 PM Monia Brett P Chief Executive Officer Feb 02 '24 Sale 49.37 23,501 1,160,303 174,138 Feb 02 07:55 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Feb 02 '24 Sale 49.60 2,125 105,404 35,825 Feb 02 07:54 PM HOUGEN ELIZABETH L EVP, Finance & CFO Feb 02 '24 Sale 49.54 2,125 105,272 92,905 Feb 02 07:55 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Feb 02 '24 Sale 49.59 2,071 102,701 49,812 Feb 02 07:55 PM Geary Richard S EVP, Chief Development Officer Feb 02 '24 Sale 50.04 1,961 98,135 87,334 Feb 02 07:54 PM O'NEIL PATRICK R. EVP CLO & General Counsel Feb 02 '24 Sale 49.67 1,961 97,410 48,661 Feb 02 07:55 PM Swayze Eric EVP Research Feb 02 '24 Sale 49.56 1,907 94,513 34,324 Feb 02 07:55 PM BENNETT C FRANK EVP, Chief Scientific Officer Feb 02 '24 Sale 49.52 1,853 91,752 79,079 Feb 02 07:54 PM Swayze Eric EVP Research Jan 31 '24 Sale 52.00 10,773 560,196 32,516 Feb 02 07:55 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 25 '24 Sale 51.75 6,450 333,788 46,802 Jan 29 05:34 PM Monia Brett P Chief Executive Officer Jan 25 '24 Sale 51.75 2,285 118,249 151,851 Jan 29 05:34 PM Monia Brett P Chief Executive Officer Jan 17 '24 Sale 50.42 32,059 1,616,319 154,136 Jan 18 05:48 PM HOUGEN ELIZABETH L EVP, Finance & CFO Jan 17 '24 Sale 50.42 8,683 437,771 90,890 Jan 18 05:48 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 17 '24 Sale 50.42 7,744 390,429 53,252 Jan 18 05:59 PM Geary Richard S EVP, Chief Development Officer Jan 17 '24 Sale 50.42 7,338 369,960 85,475 Jan 18 05:47 PM BENNETT C FRANK EVP, Chief Scientific Officer Jan 17 '24 Sale 50.42 6,745 340,063 77,323 Jan 18 05:44 PM Swayze Eric EVP Research Jan 17 '24 Sale 50.42 6,296 317,425 43,289 Jan 18 05:49 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Jan 17 '24 Sale 50.42 5,564 280,520 33,810 Jan 18 06:07 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 17 '24 Sale 50.42 5,482 276,386 47,850 Jan 18 05:48 PM Birchler Brian EVP, Corp and Development Ops Jan 17 '24 Sale 50.42 4,497 226,725 44,582 Jan 18 05:55 PM Baroldi Joseph EVP, Chief Business Officer Jan 17 '24 Sale 50.42 1,460 73,609 12,799 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 17 '24 Sale 50.42 564 28,435 1,640 Jan 18 05:44 PM Swayze Eric EVP Research Jan 17 '24 Sale 50.42 9 454 85 Jan 18 05:49 PM Baroldi Joseph EVP, Chief Business Officer Jan 16 '24 Option Exercise 0.00 1,353 0 2,204 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 16 '24 Option Exercise 0.00 3,688 0 14,259 Jan 18 05:44 PM BENNETT C FRANK EVP, Chief Scientific Officer Jan 16 '24 Option Exercise 0.00 18,314 0 84,068 Jan 18 05:44 PM HOUGEN ELIZABETH L EVP, Finance & CFO Jan 16 '24 Option Exercise 0.00 22,487 0 99,573 Jan 18 05:48 PM Monia Brett P Chief Executive Officer Jan 16 '24 Option Exercise 0.00 68,084 0 186,195 Jan 18 05:48 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Jan 16 '24 Option Exercise 0.00 15,062 0 39,374 Jan 18 06:07 PM Birchler Brian EVP, Corp and Development Ops Jan 16 '24 Option Exercise 0.00 12,080 0 49,079 Jan 18 05:55 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 16 '24 Option Exercise 0.00 20,641 0 60,996 Jan 18 05:59 PM Geary Richard S EVP, Chief Development Officer Jan 16 '24 Option Exercise 0.00 19,852 0 92,813 Jan 18 05:47 PM Swayze Eric EVP Research Jan 16 '24 Option Exercise 0.00 21 0 94 Jan 18 05:49 PM Swayze Eric EVP Research Jan 16 '24 Option Exercise 0.00 17,069 0 49,585 Jan 18 05:49 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 16 '24 Option Exercise 0.00 15,162 0 53,332 Jan 18 05:48 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 12 '24 Option Exercise 32.60 8,000 260,800 46,170 Jan 17 08:51 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 12 '24 Sale 53.50 8,000 427,999 38,170 Jan 17 08:51 PM HOUGEN ELIZABETH L EVP, Finance & CFO Dec 28 '23 Option Exercise 47.34 45,225 2,140,952 120,884 Jan 02 05:54 PM PARSHALL B LYNNE Director Dec 28 '23 Option Exercise 47.34 42,525 2,013,134 125,113 Dec 28 07:18 PM Swayze Eric EVP Research Dec 28 '23 Option Exercise 47.34 27,100 1,282,914 59,616 Jan 02 05:54 PM Birchler Brian EVP, Corp and Development Ops Dec 28 '23 Option Exercise 47.34 11,500 544,410 48,028 Jan 02 05:54 PM PARSHALL B LYNNE Director Dec 28 '23 Sale 50.19 42,525 2,134,223 82,588 Dec 28 07:18 PM Swayze Eric EVP Research Dec 28 '23 Sale 50.19 27,100 1,360,081 32,516 Jan 02 05:54 PM PARSHALL B LYNNE Director Dec 27 '23 Option Exercise 47.34 50,000 2,367,000 132,588 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 27 '23 Sale 50.23 50,000 2,511,515 82,588 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 26 '23 Option Exercise 47.34 25,113 1,188,849 107,701 Dec 28 07:18 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Dec 26 '23 Option Exercise 47.34 25,000 1,183,500 61,052 Dec 28 07:18 PM O'NEIL PATRICK R. EVP CLO & General Counsel Dec 26 '23 Option Exercise 47.34 20,825 985,856 61,180 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 26 '23 Sale 51.46 25,113 1,292,390 82,588 Dec 28 07:18 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Dec 26 '23 Sale 51.46 25,000 1,286,575 36,052 Dec 28 07:18 PM O'NEIL PATRICK R. EVP CLO & General Counsel Dec 26 '23 Sale 51.46 20,825 1,071,717 40,355 Dec 28 07:18 PM Monia Brett P Chief Executive Officer Dec 21 '23 Option Exercise 47.34 17,500 828,450 135,611 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 21 '23 Option Exercise 47.34 16,113 762,789 81,867 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 21 '23 Option Exercise 47.34 4,112 194,662 77,073 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 21 '23 Sale 49.29 17,500 862,577 118,111 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 21 '23 Sale 49.29 16,113 794,211 65,754 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 21 '23 Sale 49.29 4,112 202,681 72,961 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 72,254 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 79,461 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 124,611 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 20 '23 Sale 49.64 6,500 322,643 118,111 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 20 '23 Sale 49.64 6,500 322,643 72,961 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 20 '23 Sale 49.64 6,500 322,643 65,754 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 14 '23 Option Exercise 47.34 24,000 1,136,160 132,971 Dec 18 04:56 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 14 '23 Option Exercise 47.34 22,612 1,070,452 79,756 Dec 18 04:55 PM Geary Richard S EVP, Chief Development Officer Dec 14 '23 Option Exercise 47.34 10,613 502,419 79,532 Dec 18 04:55 PM Monia Brett P Chief Executive Officer Dec 14 '23 Sale 49.58 24,000 1,190,019 118,111 Dec 18 04:56 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 14 '23 Sale 49.58 22,612 1,121,195 65,754 Dec 18 04:55 PM Geary Richard S EVP, Chief Development Officer Dec 14 '23 Sale 49.58 10,613 526,236 72,961 Dec 18 04:55 PM KLEIN JOSEPH III Director Nov 15 '23 Sale 50.00 2,000 100,000 16,346 Nov 17 04:58 PM Swayze Eric EVP Research Oct 17 '23 Sale 47.95 52 2,493 73 Oct 18 06:40 PM Swayze Eric EVP Research Oct 16 '23 Option Exercise 0.00 125 0 125 Oct 18 06:40 PM Monia Brett P Chief Executive Officer Oct 12 '23 Sale 46.00 3,770 173,420 118,111 Oct 16 04:35 PM BENNETT C FRANK EVP, Chief Scientific Officer Sep 28 '23 Sale 46.50 4,460 207,390 65,754 Sep 29 05:20 PM PARSHALL B LYNNE Director Sep 26 '23 Sale 45.13 10,000 451,268 82,588 Sep 28 06:03 PM KLEIN JOSEPH III Director Sep 26 '23 Sale 45.13 2,000 90,254 18,346 Sep 28 06:03 PM Diaz Allene M. Director Aug 01 '23 Sale 41.05 657 26,970 12,676 Aug 03 05:20 PM KLEIN JOSEPH III Director Jul 18 '23 Sale 42.00 3,555 149,310 20,346 Jul 19 06:05 PM BERTHELSEN SPENCER R Director Jul 17 '23 Option Exercise 0.00 7,110 0 147,257 Jul 19 06:05 PM WENDER JOSEPH H Director Jul 17 '23 Option Exercise 0.00 7,110 0 112,079 Jul 19 06:08 PM Diaz Allene M. Director Jul 17 '23 Option Exercise 0.00 5,333 0 13,333 Jul 19 06:05 PM Hayden Michael R Director Jul 17 '23 Option Exercise 0.00 7,110 0 30,219 Jul 19 06:05 PM HERMAN JOAN E Director Jul 17 '23 Option Exercise 0.00 7,110 0 37,330 Jul 19 06:05 PM KLEIN JOSEPH III Director Jul 17 '23 Option Exercise 0.00 7,110 0 23,901 Jul 19 06:05 PM LOSCALZO JOSEPH Director Jul 17 '23 Option Exercise 0.00 7,110 0 41,082 Jul 19 06:06 PM PARSHALL B LYNNE Director Jul 17 '23 Option Exercise 0.00 7,110 0 92,588 Jul 19 06:06 PM Monia Brett P Chief Executive Officer Jul 07 '23 Sale 42.25 18,650 787,953 121,724 Jul 11 05:07 PM BERTHELSEN SPENCER R Director Jun 20 '23 Option Exercise 28.47 11,250 320,288 140,147 Jun 22 05:17 PM HERMAN JOAN E Director Jun 12 '23 Option Exercise 0.00 3,555 0 30,220 Jun 14 04:50 PM O'NEIL PATRICK R. EVP CLO & General Counsel May 24 '23 Sale 41.70 1,527 63,676 40,355 May 24 08:25 PM Monia Brett P Chief Executive Officer May 22 '23 Sale 40.14 4,931 197,907 140,374 May 24 08:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite